Vertex and CRISPR Therapeutics Granted Historic Approval for CASGEVY™, the World's First CRISPR/Cas9 Gene-Edited Therapy, by UK MHRA to Combat Sickle Cell Disease and Beta Thalassemia

 - First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell...

November 17, 2023 | Friday | News
SciSparc Celebrates Major Breakthrough with Positive Results Demonstrating Remarkable Impact on Alzheimer's Agitation in Treatment

SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...

November 16, 2023 | Thursday | News
Legend Biotech Secures Exclusive Global License for CAR-T Therapies Targeting DLL3.

The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies ...

November 14, 2023 | Tuesday | News
Astellas and Seagen Report Positive Results for PADCEV® Combination in Urothelial Cancer Study

– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...

October 23, 2023 | Monday | News
FDA Grants Breakthrough Designation to SeaStar Medical's Cytopheretic Device for Hepatorenal Syndrome

SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammatio...

October 19, 2023 | Thursday | News
IFF to Reveal Breakthrough Science at AAPS 2023 PharmaSci 360

IFF’s Pharma Solutions division is poised to showcase its extensive portfolio of leading excipients and present proprietary research that will addres...

October 05, 2023 | Thursday | News
Alvotech Partners with Kashiv BioSciences for Xolair® Biosimilar

The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receiv...

October 04, 2023 | Wednesday | News
Everest Medicines Secures Taiwan Approval for XERAVA® in Treating Complicated Intra-Abdominal Infections in Adults

"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...

September 28, 2023 | Thursday | News
Novartis' Lutathera® Shows Significant Progression-Free Survival in GEP-NETs

Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...

September 26, 2023 | Tuesday | News
Massive Bio and CureMatch Partner to Revolutionize Cancer Treatment with AI and Clinical Trial Accessibility.

Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representa...

July 19, 2023 | Wednesday | News
Grifols Meets Enrollment Target in Phase 3 Study of Prolastin®-C for Alpha-1-Antitrypsin Deficiency

Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifo...

July 14, 2023 | Friday | News
Next-gen Cologuard test raises non-invasive screening bar with 94% sensitivity for colorectal cancer at 91% specificity.

BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial ...

June 21, 2023 | Wednesday | News
Emgality Shows Promising Results in Landmark Migraine Prevention Trial, Says Eli Lilly Study

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...

June 17, 2023 | Saturday | News
Promising Results in Early-Stage Study of Hodgkin Lymphoma with Tessa Therapeutics' 'Off-the-Shelf' CAR-T Therapy

Safety data encouraging with no graft-versus-host-disease and no neurotoxicity Updated data highlighted in podium presentation at the 17th International...

June 16, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in